The management of PneumoBlast ™ in preclinical and animal studies has resulted in a dramatic improvement in immune signaling molecules, reducing concentrations of interleucine-1 beta, interleucine-6, interleucine-8, interleucine-17, interleucine-18 and tumor necrosis alpha Factor TNFa. Company scientists also demonstrated that PneumoBlast ™ has induced statistically significant relief in pulmonary fibrosis and lung scarring in animals inflamed with COVID-19, i. e. compared to more traditional remedies that use bone marrow-derived mesenchymatous stem cells (BMSCs). In addition, recent knowledge of the potential benefits of PneumoBlast ™ to prevent blood clotting of COVID-19. The two corporations will collaborate on a clinical examination design that satisfies the wishes of Brazilian patients.
“As the clinical and medical network learns more about the biological and medical consequences of COVID-19 infection, FibroGenesis wants to contribute to the healing characteristics that are being created lately to combat this global war against COVID-19 infection,” said Pete O’Heeron, Executive Director of FibroGenesis. “Working with R4D Biotech is another strategic step that underscores our commitment to expanding fibroblast studies globally. “